# US 2025/0129055 A1 · Glucoside derivative, and preparation method therefor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0129055 A1
- Document ID: US20250129055A1
- Status: Published application
- Kind: A1
- Application number: 18/038,001
- Filed: 2021-11-19
- Published: 2025-04-24
- Earliest claimed: 2020-11-19
- Assignees: Beijing Increase Innovative Drug Co., LTD
- Applicants: Beijing Increase Innovative Drug Co., Ltd.
- Inventors: Hongwu ZHANG; Jie HU; Chunmei XUE; Jing HU; Zhihe JU
- Web page: https://patentgrep.com/patent/US20250129055A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/351: not condensed with another ring
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 309/10: Oxygen atoms
- C07D 405/14: containing three or more hetero rings
- C07D 407/10: linked by a carbon chain containing aromatic rings
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 407/14: containing three or more hetero rings
- C07H 7/04: Carbocyclic radicals
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The glucoside derivative can be used for treatment of diabetes mellitus II or diabetes mellitus I.

## Claims

### Claim 1

A glycoside derivative, which is a compound represented by formula I or a pharmaceutically acceptable salt thereof:
wherein, A is an oxygen atom, —(CH2)m— or —NH—; m is 1, 2 or 3;
B is an oxygen atom or a sulfur atom;
R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, halogen, —CN, alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a and 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2;
alternatively, R1 and R2 together form heterocyclyl, cycloalkyl, aryl or heteroaryl fused to a benzene ring, and/or R3 and R4 together form cyclopentyl or oxacyclopentyl fused to a benzene ring;
R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen, hydroxyl, alkyl, alkoxy and alkylthio; and
R11 and R11a are independently selected from the group consisting of a hydrogen atom and alkyl;
wherein, the alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a, heterocyclyl and alkylthio are unsubstituted or further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano, alkyl, alkoxy and nitro.

### Claim 2 (depends on 1)

The glycoside derivative according to claim 1, wherein R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, halogen, —CN, C1˜C6 alkyl, C1˜C6 alkoxy, C2˜C16 alkoxyalkoxy, C3˜C6 cycloalkyl, C6˜C12 aryl, C2˜C12 heteroaryl, —O—C6˜C12 aryl, —O—C2˜C12 heteroaryl, —OCH2—C6˜C12 aryl, —OCH2—C2˜C12 heteroaryl, —O—C2˜C6 heterocyclyl, —OCH2—C2˜C6 heterocyclyl, C1˜C6 ester, —NR11R11a and 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2;
alternatively, R1 and R2 together form 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2, C3˜C6 cycloalkyl, C6˜C12 aryl or C2˜C12 heteroaryl fused to a benzene ring;
R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, hydroxyl, C1˜C6 alkyl, C1˜C6 alkoxy and C1˜C6 alkylthio; and
R11 and R11a are independently selected from the group consisting of a hydrogen atom or C1˜C6 alkyl.

### Claim 3 (depends on 1)

The glycoside derivative according to claim 1, wherein A is an oxygen atom or —CH2—;
B is an oxygen atom;
R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, fluorine, chlorine, bromine, —CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, n-hexyloxy, methoxymethoxy, ethoxymethoxy, ethoxyethoxy, n-propoxymethoxy, isopropoxymethoxy, n-propoxyethoxy, isopropoxyethoxy, cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, phenoxy, pyridyloxy, pyrimidinyloxy, pyrrolyloxy, furyloxy, thienyloxy, oxazolyloxy, benzyloxy, —OCH2-pyridyl, —OCH2-pyrimidinyl, —OCH2-pyrrolyl, —OCH2-thienyl, —OCH2-furyl, —OCH2-oxazolyl, —OCH2-thiazolyl, —OCH2-imidazolyl, —OCH2-triazolyl, methyl ester, ethyl ester, isopropyl ester, sulfonate, amino, hexahydropyridyl, hexahydropyrazinyl, morpholinyl, tetrahydropyrrolyl and tetrahydrooxazolyl; and
the above groups are unsubstituted or one or more hydrogen atoms of the above groups are further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano, C1˜C6 alkyl, C1˜C6 alkoxy and nitro.

### Claim 4 (depends on 1)

The glycoside derivative according to claim 1, wherein R1 and R2 together form cyclohexyl, phenyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, thienyl, furyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, hexahydropyridyl, hexahydropyrazinyl, morpholinyl, tetrahydropyrrolyl, tetrahydrooxazolyl or dioxane fused to a benzene ring.

### Claim 5 (depends on 1)

The glycoside derivative according to claim 1, wherein R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, hydroxyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, n-hexyloxy, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, n-pentylthio, isopentylthio and n-hexylthio.

### Claim 6 (depends on 1)

The glycoside derivative according to claim 1, which is a compound represented by formula II or a pharmaceutically acceptable salt thereof:
wherein, A is an oxygen atom, —(CH2)m— or —NH—; m is 1, 2 or 3;
B is an oxygen atom or a sulfur atom;
R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, halogen, —CN, alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a and 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2;
R10 is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkoxy and alkylthio; and
R11 and R11a are independently selected from the group consisting of a hydrogen atom and alkyl;
wherein, the alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a, heterocyclyl and alkylthio are unsubstituted or further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano, alkyl, alkoxy and nitro.

### Claim 7 (depends on 6)

The glycoside derivative according to claim 6, wherein R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, fluorine, chlorine, bromine, —CN, C1˜C6 alkyl, C1˜C6 alkoxy and C2˜C16 alkoxyalkoxy; and
R10 is selected from the group consisting of hydrogen, hydroxyl, C1˜C6 alkyl, C1˜C6 alkoxy and C1˜C6 alkylthio.

### Claim 8 (depends on 6)

The glycoside derivative according to claim 6, wherein R3 is selected from the group consisting of C1˜C3 alkyl and C1˜C3 alkoxy;
R4, R5 and R6 are hydrogen;
R10 is selected from the group consisting of hydrogen, hydroxyl, C1˜C3 alkyl, C1˜C3 alkoxy and C1˜C3 alkylthio; and
the C1˜C3 alkyl, C1˜C3 alkoxy or C1˜C3 alkylthio is unsubstituted or further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano and nitro.

### Claim 9 (depends on 1)

The glycoside derivative according to claim 1, wherein,
A is an oxygen atom or —(CH2)—;
B is an oxygen atom;
R1 and R2 together form 5 to 6-membered heterocyclyl fused to a benzene ring or form cyclobutanyl fused to a benzene ring, wherein the 5 to 6-membered heterocyclyl contains 1 or 2 heteroatoms selected from the group consisting of O and S;
R3 is selected from the group consisting of CH3(CH2)n—, CH3(CH2)n—O— and halogen, wherein
n is selected from 0, 1, 2 and 3;
R4 is hydrogen;
alternatively, R3 and R4 together form cyclopentyl or oxacyclopentyl fused to a benzene ring;
R5 and R6 are hydrogen;
R7, R5 and R9 are hydroxyl; and
R10 is selected from the group consisting of hydroxymethyl, methoxy and methylthio.

### Claim 10 (depends on 9)

The glycoside derivative according to claim 9, wherein,
A is an oxygen atom or —(CH2)—;
B is an oxygen atom;
R1 and R2 together form 5 to 6-membered heterocyclyl fused to a benzene ring or form cyclobutanyl fused to a benzene ring, wherein the 5 to 6-membered heterocyclyl contains 1 or 2 oxygen atoms;
R3 is selected from the group consisting of CH3(CH2)n—, CH3(CH2)n—O— and halogen, wherein
n is selected from 0, 1, 2 and 3;
R4 is hydrogen;
alternatively, R3 and R4 together form cyclopentyl or oxacyclopentyl fused to a benzene ring;
R5 and R6 are hydrogen;
R7, R5 and R9 are hydroxyl; and
R10 is selected from the group consisting of hydroxymethyl, methoxy and methylthio.

### Claim 11 (depends on 1)

The glycoside derivative according to claim 1, wherein,
A is an oxygen atom;
B is an oxygen atom;
R1 is C1˜C3 alkoxy;
R2 is hydrogen;
R3 is halogen, preferably fluorine, chlorine or bromine;
R4 is hydrogen;
R5 and R6 are hydrogen;
R7, R5 and R9 are hydroxyl; and
R10 is hydroxyalkyl, preferably hydroxymethyl.

### Claim 12 (depends on 1)

The glycoside derivative according to claim 1, which has a structure selected from the group consisting of:

### Claim 13 (depends on 1)

A method for producing the glycoside derivative according to claim 1, comprising:
subjecting a compound represented by formula III to a deprotection reaction to prepare a compound represented by formula I-a;
wherein, A is an oxygen atom, —(CH2)m— or —NH—; m is 1, 2 or 3;
B is an oxygen atom or a sulfur atom;
R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, halogen, —CN, alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a and 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2;
alternatively, R1 and R2 together form heterocyclyl, cycloalkyl, aryl or heteroaryl fused to a benzene ring;
R10 is hydroxymethyl; and
R11 and R11a are independently selected from the group consisting of a hydrogen atom and alkyl;
wherein the alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a, heterocyclyl and alkylthio are unsubstituted or further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano, alkyl, alkoxy and nitro; and
R12 is selected from the group consisting of alkyl, trimethylsilyl, benzyl, formyl, acetyl, tetrahydropyranyl, methoxymethyl and tert-butyldimethylsilyl.

### Claim 14 (depends on 1)

A method for producing the glycoside derivative according to claim 1, comprising:
subjecting a compound represented by formula VII to sulfurization reaction and deprotection reaction to prepare a compound represented by formula I-a;
wherein, A is an oxygen atom, —(CH2)m— or —NH—; m is 1, 2 or 3; B is an oxygen atom or a sulfur atom;
R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, halogen, —CN, alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a and 3-14 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of N, O, S, SO and SO2;
alternatively, R1 and R2 together form heterocyclyl, cycloalkyl, aryl or heteroaryl fused to a benzene ring;
R10 is methylthio; and
R11 and R11a are independently selected from the group consisting of a hydrogen atom and alkyl;
wherein, the alkyl, alkoxy, alkoxyalkoxy, cycloalkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —OCH2-aryl, —OCH2-heteroaryl, —O-heterocyclyl, —OCH2-heterocyclyl, ester, —NR11R11a, heterocyclyl and alkylthio are unsubstituted or further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, carboxyl, cyano, alkyl, alkoxy and nitro; and
R12 is selected from the group consisting of alkyl, trimethylsilyl, benzyl, formyl, acetyl, tetrahydropyranyl, methoxymethyl and tert-butyldimethylsilyl.

### Claim 15 (depends on 1)

A pharmaceutical composition, comprising the glycoside derivative according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

### Claim 16 (depends on 1)

A method for preventing, treating or alleviating diabetes mellitus and a complication thereof, comprising administering the glycoside derivative according to claim 1 to a subject in need thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the diabetes mellitus is type II diabetes mellitus or type I diabetes mellitus; and the complication is a cardiovascular disease caused by type II or type I diabetes mellitus.

### Claim 18 (depends on 13)

A pharmaceutical composition, comprising the glycoside derivative produced by the method according to claim 13, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

### Claim 19 (depends on 14)

A pharmaceutical composition, comprising the glycoside derivative produced by the method according to claim 14, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.
